# CompassHER2 RD (NCT04457596)

> T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04457596
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Alliance for Clinical Trials in Oncology
- Conditions: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2 Positive Breast Carcinoma; Invasive Breast Carcinoma; Multifocal Breast Carcinoma; Synchronous Bilateral Breast Carcinoma; Anatomic Stage I Breast Cancer AJCC v8
- Interventions: Trastuzumab Emtansine; Placebo Administration; Tucatinib; Questionnaire Administration; Quality-of-Life Assessment
- Enrollment: 1056
- Primary outcome: Modified invasive disease-free survival (iDFS)

## Indexed commentary on CompassHER2 RD so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 7
- Podcasts: 6
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=compassher2-rd-nct04457596

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04457596", "email": "<work email>"}; the inbox owner confirms by the emailed link.